Tiny XTL cuts costs, jobs

New York-based XTL Biopharmaceuticals won't be able to recover from the failure of its diabetic neuropathic pain drug bicifadine. XLT announced today that it is laying off nine employees, or 75 percent of its workforce. The remaining employees will be responsible for seeking potential assets or a company to merge into XTL, or for assisting in the liquidation on of XTL's assets. Shares of the company plunged in November when the developer announced that a mid-stage trial of its lead program bicifadine failed to hit its primary endpoint.

- here's XTL's release

Suggested Articles

The data, from two patients with severe blood disorders, are "promising” for what could be a one-and-done treatment, Cantor Fitzgerald analysts wrote.

The fund will back pharma companies as well as developers of medtech products and providers of outsourced services.

The money will fund work to develop polymers in multiple indications and an associated U.S. expansion.